Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
4.90
Dollar change
-0.19
Percentage change
-3.73
%
Index- P/E- EPS (ttm)-1.92 Insider Own26.30% Shs Outstand51.65M Perf Week5.38%
Market Cap253.43M Forward P/E- EPS next Y-1.85 Insider Trans3.03% Shs Float38.11M Perf Month0.20%
Income-82.44M PEG- EPS next Q-0.43 Inst Own69.42% Short Float4.76% Perf Quarter63.88%
Sales0.00M P/S- EPS this Y7.98% Inst Trans0.10% Short Ratio3.02 Perf Half Y70.73%
Book/sh2.26 P/B2.17 EPS next Y-7.17% ROA-52.37% Short Interest1.81M Perf Year169.23%
Cash/sh2.54 P/C1.93 EPS next 5Y- ROE-70.94% 52W Range1.43 - 6.85 Perf YTD74.38%
Dividend Est.- P/FCF- EPS past 5Y-49.79% ROI-59.34% 52W High-28.47% Beta2.64
Dividend TTM- Quick Ratio6.82 Sales past 5Y0.00% Gross Margin- 52W Low242.66% ATR (14)0.43
Dividend Ex-Date- Current Ratio6.82 EPS Y/Y TTM23.34% Oper. Margin0.00% RSI (14)54.03 Volatility11.17% 9.34%
Employees54 Debt/Eq0.22 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price10.60
Option/ShortYes / Yes LT Debt/Eq0.19 EPS Q/Q35.12% Payout- Rel Volume0.67 Prev Close5.09
Sales Surprise- EPS Surprise27.04% Sales Q/Q- EarningsMar 12 BMO Avg Volume600.99K Price4.90
SMA205.19% SMA5016.65% SMA20048.56% Trades Volume404,260 Change-3.73%
Date Action Analyst Rating Change Price Target Change
Jul-14-23Initiated Piper Sandler Overweight
Jun-30-23Upgrade Stifel Hold → Buy $2 → $10
Jun-28-23Upgrade H.C. Wainwright Neutral → Buy $11
Jun-27-23Upgrade Wedbush Neutral → Outperform $10
Mar-29-22Downgrade Wedbush Outperform → Neutral
Mar-22-22Downgrade H.C. Wainwright Buy → Neutral
Sep-30-21Initiated Stifel Hold $10
Jan-07-21Initiated Wedbush Outperform $45
Nov-24-20Initiated Berenberg Buy $58
May-04-20Initiated H.C. Wainwright Buy $53
Mar-22-24 09:55AM
Mar-14-24 05:31AM
Mar-12-24 08:32AM
08:00AM
Mar-05-24 04:30PM
08:00AM Loading…
Feb-28-24 08:00AM
Jan-04-24 08:00AM
Dec-13-23 07:00AM
Nov-07-23 08:00AM
Nov-06-23 08:07AM
07:48AM
07:45AM
Oct-20-23 12:54PM
Oct-14-23 12:30PM
Oct-04-23 12:14PM
12:34PM Loading…
Sep-18-23 12:34PM
07:00AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-17-23 09:56AM
Aug-11-23 07:35AM
07:30AM
Jul-25-23 07:43AM
Jul-16-23 10:05AM
Jun-29-23 08:57PM
05:48PM
Jun-28-23 04:23PM
07:15AM
Jun-27-23 07:00AM
Jun-13-23 08:00AM
08:00AM Loading…
Jun-02-23 08:00AM
May-18-23 10:17AM
May-09-23 07:46AM
07:30AM
Apr-18-23 08:00AM
Apr-17-23 04:01PM
Mar-09-23 07:52AM
07:30AM
Feb-27-23 08:00AM
Feb-15-23 05:46AM
Jan-19-23 05:41AM
Jan-05-23 08:00AM
Dec-19-22 08:00AM
Dec-12-22 08:00AM
Dec-09-22 09:35AM
09:04AM
Nov-09-22 08:00AM
Nov-08-22 08:00AM
Oct-26-22 08:00AM
Sep-06-22 08:00AM
Aug-28-22 09:41AM
Aug-09-22 08:00AM
Aug-03-22 08:00AM
Aug-01-22 08:55AM
Jul-02-22 08:29AM
Jun-06-22 08:00AM
Jun-01-22 07:00AM
May-17-22 07:00AM
May-12-22 04:30PM
May-11-22 04:30PM
Apr-28-22 12:52PM
Apr-25-22 09:00AM
Apr-18-22 07:00AM
Apr-07-22 04:30PM
07:00AM
Mar-17-22 05:00PM
Mar-02-22 08:00AM
Feb-22-22 08:00AM
Feb-16-22 05:28AM
Jan-11-22 07:00AM
Jan-10-22 07:00AM
Jan-05-22 08:00AM
Nov-18-21 05:27AM
Nov-08-21 04:05PM
07:45AM
Oct-08-21 04:05PM
Oct-04-21 11:02AM
Sep-30-21 04:35PM
Sep-21-21 04:05PM
07:45AM
Aug-12-21 08:22AM
Aug-10-21 07:45AM
Aug-04-21 07:45AM
Aug-02-21 02:26AM
Jul-29-21 03:53PM
May-19-21 05:00PM
May-17-21 07:45AM
May-07-21 07:45AM
May-04-21 02:01AM
Apr-28-21 10:38AM
Apr-10-21 08:30AM
Mar-25-21 07:45AM
Mar-10-21 04:58PM
Mar-02-21 04:05PM
Feb-23-21 07:45AM
Feb-11-21 04:15PM
Feb-02-21 11:51PM
07:32PM
Jan-20-21 07:45AM
Jan-05-21 07:45AM
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOTECH GROWTH N V10% OwnerOct 17 '23Buy2.34400,000934,0808,517,839Oct 19 03:08 PM
Behbahani AliDirectorJul 05 '23Buy5.001,000,0005,000,0004,448,757Jul 06 04:45 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJul 05 '23Buy5.00935,8504,679,2503,213,828Jul 07 04:30 PM
BIOTECH GROWTH N V10% OwnerJun 30 '23Buy5.001,000,0005,000,0008,117,839Jul 03 03:36 PM
BIOTECH GROWTH N V10% OwnerJun 27 '23Buy5.491,740,0009,555,0367,117,839Jun 29 01:37 PM
Epstein David M.SEE REMARKSJun 27 '23Sale6.7025,000167,500671,423Jun 28 04:02 PM
Last Close
Mar 27 04:00PM ET
70.16
Dollar change
-0.81
Percentage change
-1.14
%
CRSP CRISPR Therapeutics AG daily Stock Chart
Index- P/E- EPS (ttm)-1.97 Insider Own5.21% Shs Outstand80.04M Perf Week-3.81%
Market Cap5.91B Forward P/E- EPS next Y-4.08 Insider Trans-3.10% Shs Float79.80M Perf Month-21.27%
Income-153.61M PEG- EPS next Q-1.45 Inst Own64.27% Short Float18.45% Perf Quarter7.39%
Sales371.21M P/S15.91 EPS this Y-199.14% Inst Trans-0.05% Short Ratio7.48 Perf Half Y52.99%
Book/sh23.52 P/B2.98 EPS next Y29.75% ROA-6.87% Short Interest14.72M Perf Year61.55%
Cash/sh20.12 P/C3.49 EPS next 5Y- ROE-8.17% 52W Range37.55 - 91.10 Perf YTD12.08%
Dividend Est.- P/FCF- EPS past 5Y10.83% ROI-7.29% 52W High-22.99% Beta1.76
Dividend TTM- Quick Ratio17.54 Sales past 5Y33402.13% Gross Margin65.88% 52W Low86.84% ATR (14)3.35
Dividend Ex-Date- Current Ratio17.54 EPS Y/Y TTM76.72% Oper. Margin-53.64% RSI (14)39.07 Volatility3.37% 4.18%
Employees407 Debt/Eq0.13 Sales Y/Y TTM30885.48% Profit Margin-41.38% Recom2.28 Target Price85.74
Option/ShortYes / Yes LT Debt/Eq0.12 EPS Q/Q177.83% Payout- Rel Volume0.68 Prev Close70.97
Sales Surprise42.76% EPS Surprise1559.13% Sales Q/Q3353333.33% EarningsFeb 21 BMO Avg Volume1.97M Price70.16
SMA20-8.52% SMA50-4.14% SMA20018.52% Trades Volume1,340,687 Change-1.14%
Date Action Analyst Rating Change Price Target Change
Feb-15-24Initiated Wolfe Research Peer Perform
Dec-11-23Downgrade TD Cowen Market Perform → Underperform $30
Oct-17-23Downgrade Cantor Fitzgerald Overweight → Neutral
Sep-27-23Initiated Mizuho Buy $82
Aug-17-23Upgrade Citigroup Neutral → Buy
May-30-23Initiated William Blair Outperform $75
Apr-13-23Initiated Cantor Fitzgerald Overweight $72
Mar-21-23Initiated Bernstein Mkt Perform $44
Mar-17-23Initiated Bryan Garnier Buy $70
Mar-07-23Initiated Robert W. Baird Neutral $46
Mar-27-24 04:50AM
Mar-25-24 06:15PM
Mar-24-24 10:08AM
Mar-23-24 06:45AM
Mar-22-24 11:30AM
04:19PM Loading…
Mar-21-24 04:19PM
Mar-20-24 01:49PM
Mar-19-24 06:15PM
12:07AM
Mar-17-24 08:50AM
Mar-16-24 08:45AM
Mar-14-24 08:15AM
Mar-13-24 02:25PM
08:30AM
Mar-06-24 02:45PM
06:53PM Loading…
Mar-05-24 06:53PM
Mar-04-24 11:02AM
08:48AM
Feb-29-24 05:32PM
06:31AM
05:50AM
Feb-27-24 12:00PM
Feb-26-24 08:50AM
06:45AM
Feb-23-24 10:01AM
Feb-22-24 07:37AM
04:00AM
Feb-21-24 04:32PM
10:15AM
07:30AM
05:02AM Loading…
Feb-20-24 05:02AM
Feb-19-24 04:08PM
01:45AM
Feb-16-24 02:19PM
07:31AM
Feb-15-24 08:30AM
Feb-14-24 08:15AM
Feb-13-24 01:22PM
10:00AM
08:30AM
02:30AM
Feb-10-24 05:09PM
Feb-09-24 06:00PM
Feb-08-24 02:59AM
Feb-07-24 10:00AM
09:09AM
Feb-05-24 08:00AM
Feb-04-24 02:35PM
Feb-02-24 06:00PM
Feb-01-24 09:10PM
Jan-31-24 12:28PM
Jan-30-24 05:10AM
05:02AM
Jan-28-24 05:10AM
Jan-25-24 06:15PM
08:32AM
Jan-24-24 09:45AM
Jan-23-24 09:30AM
Jan-22-24 09:12AM
05:05AM
Jan-21-24 09:37AM
08:00AM
Jan-20-24 06:50AM
Jan-19-24 06:15PM
Jan-16-24 04:08PM
04:01PM
08:15AM
Jan-15-24 04:56PM
06:30AM
05:19AM
Jan-14-24 01:30PM
05:10AM
Jan-13-24 06:05AM
05:20AM
Jan-10-24 06:00AM
Jan-09-24 06:15PM
Jan-08-24 09:17AM
07:00AM
05:00AM
Jan-06-24 05:00AM
Jan-04-24 05:00AM
Jan-03-24 12:17PM
08:30AM
Jan-01-24 09:05AM
Dec-31-23 10:30AM
08:45AM
Dec-30-23 06:50AM
12:09AM
Dec-25-23 05:30AM
Dec-22-23 05:02PM
05:27AM
Dec-21-23 08:30AM
05:51AM
Dec-20-23 11:04AM
09:43AM
05:00AM
Dec-19-23 05:11PM
05:00AM
Dec-18-23 05:30AM
Dec-17-23 08:45AM
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kulkarni SamarthChief Executive OfficerMar 15 '24Option Exercise19.1220,000382,400228,122Mar 18 05:45 PM
Kulkarni SamarthChief Executive OfficerMar 15 '24Sale72.4820,0001,449,628208,122Mar 18 05:45 PM
Prasad RajuChief Financial OfficerMar 15 '24Sale72.693,524256,1606,476Mar 18 05:45 PM
Kulkarni SamarthChief Executive OfficerMar 12 '24Sale74.444,583341,159208,122Mar 12 05:45 PM
KASINGER JAMES R.General Counsel and SecretaryMar 12 '24Sale74.441,14685,30861,174Mar 12 05:45 PM
Kulkarni SamarthChief Executive OfficerMar 11 '24Sale78.269,802767,105203,705Mar 12 05:45 PM
KASINGER JAMES R.General Counsel and SecretaryMar 11 '24Sale78.262,801219,20660,070Mar 12 05:45 PM
Kulkarni SamarthChief Executive OfficerFeb 20 '24Sale79.676,370507,498194,257Feb 21 05:45 PM
KASINGER JAMES R.General Counsel and SecretaryFeb 20 '24Sale79.671,913152,40957,371Feb 21 05:45 PM
Kulkarni SamarthChief Executive OfficerFeb 15 '24Option Exercise19.1220,000382,400207,377Feb 16 05:45 PM
Kulkarni SamarthChief Executive OfficerFeb 15 '24Sale80.3620,0001,607,177187,377Feb 16 05:45 PM
Kulkarni SamarthChief Executive OfficerJan 29 '24Option Exercise19.1250,000956,000237,377Jan 31 05:45 PM
Kulkarni SamarthChief Executive OfficerJan 29 '24Sale60.5150,0003,025,573187,377Jan 31 05:45 PM
Kulkarni SamarthChief Executive OfficerJan 16 '24Option Exercise19.1220,000382,400207,377Jan 18 05:45 PM
Kulkarni SamarthChief Executive OfficerJan 16 '24Sale62.5020,0001,250,058187,377Jan 18 05:45 PM
Kulkarni SamarthChief Executive OfficerMay 30 '23Option Exercise19.1225,000478,000412,377Jun 01 05:44 PM
Kulkarni SamarthChief Executive OfficerMay 30 '23Sale64.8825,0001,621,894387,377Jun 01 05:44 PM
Kulkarni SamarthChief Executive OfficerApr 25 '23Option Exercise19.1225,000478,000412,377Apr 27 05:37 PM
Kulkarni SamarthChief Executive OfficerApr 25 '23Sale50.6725,0001,266,638387,377Apr 27 05:37 PM
Kulkarni SamarthChief Executive OfficerMar 29 '23Option Exercise19.1225,000478,000412,377Mar 31 05:49 PM
Kulkarni SamarthChief Executive OfficerMar 29 '23Sale44.4625,0001,111,504387,377Mar 31 05:49 PM